Abstract
Cellular quiescence is defined with reversible nonproliferating state and featured with a low metabolic state such as decreased glycolysis, reduced translation rates, and activation of autophagy. As signal for quiescence or dormancy, reduced cell growth and biosynthesis inactivating the TOR kinase are essential, but cellular quiescence is not always associated with reduced metabolism since it is also possible to achieve a state of cellular quiescence in which glucose uptake, glycolysis, and flux through central carbon metabolism are not reduced. However, in contrast to normal cells, cancer cells, especially cancer stem or dormancy cells, intrinsic and acquired resistance led to resistance to cancer therapeutics, but can be reversed with the acquisition of chemoquiescence. The development of new drug combinations or strategy to treat the highly aggressive and metastatic cancers including relapsed leukemias, melanoma, and head and neck, brain, lung, breast, ovary, prostate, pancreas as well as gastrointestinal cancers can be feasible with the combination of chemoquiescence agent, in which cancer stem cells (CSCs) or tumor dormancy can be possibly eradicated or removed. Therefore, active investigations of metformin or chloroquine as well as other drugs under revisited study, such as potassium channel-inhibiting acid pump antagonist, sonic hedgehog inhibitors, and Akt inhibitor, are actively performing under the hopeful vision of chemoquiescence, aiming at achieving complete cancer cure as well as prevention of cancer recurrence far beyond the scope of current chemotherapy or chemoprevention. In this chapter, the evolving concept of chemoquiescence or cancer dormancy will be introduced accompanied by introduction of some novel drug development targeted for chemoquiescence. Now, we should seize as well as eradicate rotten root of cancer for cure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18(5):460–466. doi:10.1016/j.copbio.2007.10.007
Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23(43):7274–7282. doi:10.1038/sj.onc.1207947
Alison MR, Lin WR, Lim SM, Nicholson LJ (2012) Cancer stem cells: in the line of fire. Cancer Treat Rev 38(6):589–598. doi:10.1016/j.ctrv.2012.03.003
Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294(2):139–146. doi:10.1016/j.canlet.2010.03.004
Balic A, Draeby Sorensen M, Trabulo SM, Sainz B Jr, Cioffi M, Vieira CR, Miranda-Lorenzo I, Hidalgo M, Kleeff J, Erkan M, Heeschen C (2014) Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol Cancer Ther. doi:10.1158/1535-7163.MCT-13-0948
Borst P (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2(5):120066. doi:10.1098/rsob.120066
Buczacki S, Davies RJ, Winton DJ (2011) Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer 105(9):1253–1259. doi:10.1038/bjc.2011.362
Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K, Bageritz J, Grabe N, von Deimling A, Beckhove P, Mogler C, Goidts V, Unterberg A, Eckstein V, Herold-Mende C (2014) Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. J Pathol. doi:10.1002/path.4366
Chen K, Huang YH, Chen JL (2013) Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 34(6):732–740. doi:10.1038/aps.2013.27
Cheng L, Alexander R, Zhang S, Pan CX, MacLennan GT, Lopez-Beltran A, Montironi R (2011) The clinical and therapeutic implications of cancer stem cell biology. Expert Rev Anticancer Ther 11(7):1131–1143. doi:10.1586/era.11.82
Cheung TH, Rando TA (2013) Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol 14(6):329–340. doi:10.1038/nrm3591
Croker AK, Allan AL (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12(2):374–390. doi:10.1111/j.1582-4934.2007.00211.x
Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA (2011) Metformin: multi-faceted protection against cancer. Oncotarget 2(12):896–917
Firat E, Weyerbrock A, Gaedicke S, Grosu AL, Niedermann G (2012) Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote gamma-irradiation-induced cell death in primary stem-like glioma cells. PLoS One 7(10):e47357. doi:10.1371/journal.pone.0047357
Giancotti FG (2013) Mechanisms governing metastatic dormancy and reactivation. Cell 155(4):750–764. doi:10.1016/j.cell.2013.10.029
Hadnagy A, Gaboury L, Beaulieu R, Balicki D (2006) SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312(19):3701–3710. doi:10.1016/j.yexcr.2006.08.030
Hahnfeldt P (2013) The host support niche as a control point for tumor dormancy: implications for tumor development and beyond. Adv Exp Med Biol 734:19–35. doi:10.1007/978-1-4614-1445-2_2
Hittelman WN, Liao Y, Wang L, Milas L (2010) Are cancer stem cells radioresistant? Future Oncol 6(10):1563–1576. doi:10.2217/fon.10.121
Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ (2008) Cancer stem cells: how can we target them? Curr Med Chem 15(30):3171–3184
Kimura T, Takabatake Y, Takahashi A, Isaka Y (2013) Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 73(1):3–7. doi:10.1158/0008-5472.CAN-12-2464
Kleffel S, Schatton T (2013) Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol 734:145–179. doi:10.1007/978-1-4614-1445-2_8
Kondo T (2007) Stem cell-like cancer cells in cancer cell lines. Cancer Biomarkers 3(4–5):245–250
Korkaya H, Wicha MS (2007) Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 21(5):299–310
Li F, Tiede B, Massague J, Kang Y (2007) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17(1):3–14. doi:10.1038/sj.cr.7310118
Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117(5):1175–1183. doi:10.1172/JCI31537
Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L (2011) Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem 18(18):2715–2726
Maugeri-Sacca M, Vigneri P, De Maria R (2011) Cancer stem cells and chemosensitivity. Clin Cancer Res 17(15):4942–4947. doi:10.1158/1078-0432.CCR-10-2538
Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A (2012) Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 8(2):200–212. doi:10.4161/auto.8.2.18554
Milas L, Hittelman WN (2009) Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 19(2):96–105. doi:10.1016/j.semradonc.2008.11.004
Mimeault M, Batra SK (2008) Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med 50(1):3–18
Mimeault M, Batra SK (2010) New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol 25(8):1057–1073
Moserle L, Ghisi M, Amadori A, Indraccolo S (2010) Side population and cancer stem cells: therapeutic implications. Cancer Lett 288(1):1–9. doi:10.1016/j.canlet.2009.05.020
Mueller MT, Hermann PC, Heeschen C (2010) Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed) 2:602–613
Naumov GN, Akslen LA, Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5(16):1779–1787
Naumov GN, Folkman J, Straume O, Akslen LA (2008) Tumor-vascular interactions and tumor dormancy. APMIS 116(7–8):569–585. doi:10.1111/j.1600-0463.2008.01213.x
Ni C, Huang J (2013) Dynamic regulation of cancer stem cells and clinical challenges. Clin Transl Oncol 15(4):253–258. doi:10.1007/s12094-012-0927-7
Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 65(14):6207–6219. doi:10.1158/0008-5472.CAN-05-0592
Quesnel B (2013) Tumor dormancy: long-term survival in a hostile environment. Adv Exp Med Biol 734:181–200. doi:10.1007/978-1-4614-1445-2_9
Rahim R, Strobl JS (2009) Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20(8):736–745. doi:10.1097/CAD.0b013e32832f4e50
Rezza A, Sennett R, Rendl M (2014) Adult stem cell niches: cellular and molecular components. Curr Top Dev Biol 107:333–372. doi:10.1016/B978-0-12-416022-4.00012-3
Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64(11):937–946. doi:10.1136/jcp.2011.090456
Roth S, Fodde R (2011) Quiescent stem cells in intestinal homeostasis and cancer. Cell Commun Adhes 18(3):33–44. doi:10.3109/15419061.2011.615422
Shanware NP, Bray K, Abraham RT (2013) The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 53:89–106. doi:10.1146/annurev-pharmtox-010611-134717
Solomon VR, Lee H (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625(1–3):220–233. doi:10.1016/j.ejphar.2009.06.063
Srivastava S, Krishna S (2009) Cancer stem cells: an approach to identify newer therapeutic targets. J Stem Cells 4(2):123–131
Vazquez-Martin A, Lopez-Bonetc E, Cufi S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA (2011) Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 14(4–5):212–223. doi:10.1016/j.drup.2011.04.003
Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP (2012) The develo** cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 13(2):83–89. doi:10.1016/S1470-2045(11)70257-1
Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nat Med 19(11):1450–1464. doi:10.1038/nm.3391
Wang SH, Lin SY (2013) Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention. Exp Hematol Oncol 2(1):29. doi:10.1186/2162-3619-2-29
Wang C, **e J, Guo J, Manning HC, Gore JC, Guo N (2012) Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 28(4):1301–1308. doi:10.3892/or.2012.1951
Watanabe M (2014) Adult tissue stem cell therapy for gastrointestinal diseases. J Gastroenterol Hepatol. doi:10.1111/jgh.12555
Wells A, Griffith L, Wells JZ, Taylor DP (2013) The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res 73(13):3811–3816. doi:10.1158/0008-5472.CAN-13-0356
Wu C, Alman BA (2008) Side population cells in human cancers. Cancer Lett 268(1):1–9. doi:10.1016/j.canlet.2008.03.048
Yan W, Chen Y, Yao Y, Zhang H, Wang T (2013) Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell Int 13(1):62. doi:10.1186/1475-2867-13-62
Yu Y, Zhu Z (2013) Cell dormancy and tumor refractory. Anticancer Agents Med Chem 13(2):199–202
Yu Z, Pestell TG, Lisanti MP, Pestell RG (2012) Cancer stem cells. Int J Biochem Cell Biol 44(12):2144–2151. doi:10.1016/j.biocel.2012.08.022
Yumoto K, Eber MR, Berry JE, Taichman RS, Shiozawa Y (2014) Molecular pathways: niches in metastatic dormancy. Clin Cancer Res. doi:10.1158/1078-0432.CCR-13-0897
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this paper
Cite this paper
Park, J.M. et al. (2015). Seizing Cancer Completely Through Specific Ablating Cancer Stem Cell: The Royal Road to Chemoquiescence. In: Gandhi, V., Mehta, K., Grover, R., Pathak, S., Aggarwal, B. (eds) Multi-Targeted Approach to Treatment of Cancer. Adis, Cham. https://doi.org/10.1007/978-3-319-12253-3_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-12253-3_23
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-12252-6
Online ISBN: 978-3-319-12253-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)